Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
SEK 3.84
(-2.04%)
SEK 3.84
(-2.04%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 454 Thousand SEK | -98.52% |
| 2022 | 30.67 Million SEK | 11116.95% |
| 2021 | 273.5 Thousand SEK | -59.39% |
| 2020 | 673.5 Thousand SEK | -37.26% |
| 2019 | 1.07 Million SEK | -27.15% |
| 2018 | 1.47 Million SEK | -21.35% |
| 2017 | 1.87 Million SEK | 2448.98% |
| 2016 | 73.5 Thousand SEK | 0.0% |
| 2015 | 73.5 Thousand SEK | 0.0% |
| 2014 | 73.5 Thousand SEK | 0.0% |
| 2013 | 73.5 Thousand SEK | -31.2% |
| 2012 | 106.83 Thousand SEK | -61.87% |
| 2011 | 280.16 Thousand SEK | -15.95% |
| 2010 | 333.33 Thousand SEK | 108.33% |
| 2009 | 160 Thousand SEK | 1175.82% |
| 2008 | 12.54 Thousand SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 454 Thousand SEK | 0.0% |
| 2024 Q3 | 231 Thousand SEK | 0.0% |
| 2024 Q2 | 454 Thousand SEK | 0.0% |
| 2023 Q1 | 28.73 Million SEK | -6.33% |
| 2023 Q4 | 454 Thousand SEK | 93.19% |
| 2023 FY | 454 Thousand SEK | -98.52% |
| 2023 Q3 | 235 Thousand SEK | -99.48% |
| 2023 Q2 | 45.11 Million SEK | 57.0% |
| 2022 Q1 | 100 Thousand SEK | -63.44% |
| 2022 Q4 | 30.67 Million SEK | 0.0% |
| 2022 Q3 | - SEK | 0.0% |
| 2022 FY | 30.67 Million SEK | 11116.95% |
| 2022 Q2 | - SEK | -100.0% |
| 2021 Q1 | 500 Thousand SEK | -25.76% |
| 2021 Q3 | 300 Thousand SEK | -25.0% |
| 2021 Q4 | 273.5 Thousand SEK | -8.83% |
| 2021 FY | 273.5 Thousand SEK | -59.39% |
| 2021 Q2 | 400 Thousand SEK | -20.0% |
| 2020 Q3 | 700 Thousand SEK | -12.5% |
| 2020 FY | 673.5 Thousand SEK | -37.26% |
| 2020 Q1 | 900 Thousand SEK | -16.16% |
| 2020 Q2 | 800 Thousand SEK | -11.11% |
| 2020 Q4 | 673.5 Thousand SEK | -3.79% |
| 2019 FY | 1.07 Million SEK | -27.15% |
| 2019 Q2 | 21.2 Million SEK | 1530.77% |
| 2019 Q3 | 21.1 Million SEK | -0.47% |
| 2019 Q4 | 1.07 Million SEK | -94.91% |
| 2019 Q1 | 1.3 Million SEK | -11.77% |
| 2018 Q1 | 1.7 Million SEK | -9.26% |
| 2018 Q4 | 1.47 Million SEK | -1.77% |
| 2018 Q3 | 1.5 Million SEK | -6.25% |
| 2018 Q2 | 1.6 Million SEK | -5.88% |
| 2018 FY | 1.47 Million SEK | -21.35% |
| 2017 Q2 | 2 Million SEK | 0.0% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 FY | 1.87 Million SEK | 2448.98% |
| 2017 Q4 | 1.87 Million SEK | -1.39% |
| 2017 Q3 | 1.9 Million SEK | -5.0% |
| 2016 FY | 73.5 Thousand SEK | 0.0% |
| 2016 Q4 | 73.5 Thousand SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 FY | 73.5 Thousand SEK | 0.0% |
| 2015 Q4 | 73.5 Thousand SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q4 | 73.5 Thousand SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 FY | 73.5 Thousand SEK | 0.0% |
| 2014 Q1 | - SEK | -100.0% |
| 2013 Q3 | 3 Million SEK | 67.67% |
| 2013 Q4 | 73.5 Thousand SEK | -97.55% |
| 2013 FY | 73.5 Thousand SEK | -31.2% |
| 2013 Q1 | 73.5 Thousand SEK | -31.2% |
| 2013 Q2 | 1.78 Million SEK | 2334.26% |
| 2012 FY | 106.83 Thousand SEK | -61.87% |
| 2012 Q4 | 106.83 Thousand SEK | 0.0% |
| 2012 Q2 | 43.33 Thousand SEK | -50.94% |
| 2012 Q3 | - SEK | -100.0% |
| 2012 Q1 | 88.33 Thousand SEK | -68.47% |
| 2011 Q3 | 83.33 Thousand SEK | -50.0% |
| 2011 Q4 | 280.16 Thousand SEK | 236.2% |
| 2011 Q1 | 249.99 Thousand SEK | -25.0% |
| 2011 FY | 280.16 Thousand SEK | -15.95% |
| 2011 Q2 | 166.66 Thousand SEK | -33.33% |
| 2010 Q4 | 333.33 Thousand SEK | 2122.21% |
| 2010 Q1 | 120 Thousand SEK | -25.0% |
| 2010 Q2 | 80 Thousand SEK | -33.33% |
| 2010 FY | 333.33 Thousand SEK | 108.33% |
| 2010 Q3 | 15 Thousand SEK | -81.25% |
| 2009 Q3 | - SEK | 0.0% |
| 2009 FY | 160 Thousand SEK | 1175.82% |
| 2009 Q4 | 160 Thousand SEK | 0.0% |
| 2009 Q2 | - SEK | 0.0% |
| 2008 Q4 | 12.54 Thousand SEK | 0.0% |
| 2008 FY | 12.54 Thousand SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.972% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.972% |
| Arcoma AB | 3.87 Million SEK | 88.278% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 99.805% |
| BICO Group AB (publ) | 1.85 Billion SEK | 99.976% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 99.727% |
| CellaVision AB (publ) | 64.7 Million SEK | 99.298% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | 74.778% |
| Duearity AB (publ) | 10.58 Million SEK | 95.71% |
| Dignitana AB (publ) | 19.1 Million SEK | 97.624% |
| Episurf Medical AB (publ) | 5.2 Million SEK | 91.269% |
| Getinge AB (publ) | 8.07 Billion SEK | 99.994% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | 94.497% |
| Iconovo AB (publ) | 7.72 Million SEK | 94.123% |
| Integrum AB (publ) | 6.42 Million SEK | 92.933% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -120.363% |
| Mentice AB (publ) | 9.55 Million SEK | 95.25% |
| OssDsign AB (publ) | 3.15 Million SEK | 85.587% |
| Paxman AB (publ) | 13.57 Million SEK | 96.654% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | 97.81% |
| SciBase Holding AB (publ) | 6.79 Million SEK | 93.321% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | 98.572% |
| Sedana Medical AB (publ) | 4.3 Million SEK | 89.457% |
| Senzime AB (publ) | 11.46 Million SEK | 96.041% |
| SpectraCure AB (publ) | 6.71 Million SEK | 93.241% |
| Stille AB | 62.94 Million SEK | 99.279% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 99.978% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | 98.556% |